The Global Albinism Drug Market Size is Anticipated to Exceed USD 0.39 Billion by 2033, Growing at a CAGR of 4.55% from 2023 to 2033.Albinism is a genetic condition that reduces the production of melanin, causing a fair skin tone, light eyes, and increased susceptibility to skin and eye conditions.